iTeos Therapeutics Announces Appointment of Dr. Jean-Pierre Bizzari to the Company's Board of Directors

Share Article

iTeos Therapeutics SA announced today the appointment of Dr. Jean-Pierre Bizzari to the company's board of directors. Dr. Bizzari adds further depth to iTeos' board by bringing knowledge and experience gained through a long clinical and operational career for oncology therapeutics.

iTeos Therapeutics SA announced today the appointment of Dr. Jean-Pierre Bizzari to the company's board of directors. Dr. Bizzari adds further depth to iTeos' board by bringing knowledge and experience gained through a long clinical and operational career for oncology therapeutics.

"We welcome Dr. Bizzari to our board of directors," said Dr Philippe Guinot, iTeos Therapeutics’ Chairman. "His extensive product development and clinical experiences in the oncology segment of our industry will prove invaluable as we continue to build iTeos’ product pipeline in the field of immuno-oncology."

“It is an honor and a privilege to be on this board. I do believe that targeting metabolism of the tumor environment to develop small molecules immune-modulators is the right approach for cancer therapy, and I do expect a lot of positive developments in a near future” said Dr Bizzari.

Dr. Bizzari was Executive President Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In this position, Dr. Bizzari was responsible for Celgene's clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX®(romidepsin) and ABRAXANE® (nab-paclitaxel). Prior to his role at Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Aventis, Sanofi and Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek®(rasburicase). Dr Bizzari is Board Member of Transgene, Halozyme & Celator as well as the EORTC. He is also a member of the Scientific Advisory Board of France's National Cancer Institute

About iTeos Therapeutics SA
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy. iTeos combines unparalleled expertise in tumor immunology, cancer immunotherapy and drug discovery. The company entered into a strategic alliance with Pfizer in December 2014, and is now strongly positioned to deliver the next generation of cancer immunotherapies. iTeos is developing partnerships with charities, top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alfred Gray
Visit website